Sofia I. Bär

发表

Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer

B. Nitzsche, A. Dittmer, R. Schobert, 2022, International journal of oncology.

Revisiting the anticancer properties of phosphane(9-ribosylpurine-6-thiolato)gold(I) complexes and their 9H-purine precursors

R. Schobert, Sofia I. Bär, Luisa Kober, 2022, JBIC Journal of Biological Inorganic Chemistry.

Synthesis and Bioactivity of Ancorinoside B, a Marine Diglycosyl Tetramic Acid

R. Schobert, H. Schrey, Sofia I. Bär, 2021, Marine drugs.

Antitumoral effects of mitochondria-targeting neutral and cationic cis-[bis(1,3-dibenzylimidazol-2-ylidene)Cl(L)]Pt(ii) complexes.

V. Brabec, R. Schobert, H. Kostrhunova, 2020, Dalton transactions.

Trans-[bis(benzimidazol-2-ylidene)dichlorido]platinum(II) complexes with peculiar modes of action and activity against cisplatin-resistant cancer cells.

R. Schobert, Sofia I. Bär, Sebastian W. Schleser, 2022, Journal of inorganic biochemistry.

3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors

R. Schobert, B. Biersack, Sofia I. Bär, 2022, Investigational new drugs.

Novel Anticancer NHC*-Gold(I) Complexes Inspired by Lepidiline A

H. Müller‐Bunz, R. Schobert, M. Tacke, 2020, Molecules.

New chimeric HDAC inhibitors for the treatment of colorectal cancer

B. Nitzsche, M. Höpfner, R. Schobert, 2022, Archiv der Pharmazie.

Synthesis and antiproliferative effect of the proposed stereoisomer of the marine sponge metabolite halisphingosine A.

R. Schobert, Sofia I. Bär, Alexander Bär, 2020, Organic & biomolecular chemistry.

Synthesis and Bioactivity of Ophiofuranones A and B.

R. Schobert, H. Schrey, Sofia I. Bär, 2022, Journal of Organic Chemistry.